AbbVie reports positive results for epcoritamab in EPCORE NHL-1 trial
Topline results from the follicular lymphoma cohort demonstrated an ORR of 82%, which surpassed the protocol prespecified threshold…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
28 Jun 23
Topline results from the follicular lymphoma cohort demonstrated an ORR of 82%, which surpassed the protocol prespecified threshold…
28 Jun 23
The once-daily fixed-dose combination has been approved for type-2 diabetes by the NMPA as an adjunct to diet…
28 Jun 23
The approval of the IgG4 monoclonal antibody is for adult patients suffering from the rare long-term autoimmune disorder…
28 Jun 23
COSBI will provide InSilicoTrials with its unique computational models and simulation tools, leveraging their expertise in systems biology…
28 Jun 23
Submissions based on positive Phase 3 data from BENEGENE-2 trial
27 Jun 23
Camzyos is an allosteric and reversible inhibitor that works by modulating the number of myosin heads that can…
27 Jun 23
The combined company will have a significantly wider geographic footprint with extensive coverage of Asian and Middle Eastern…
27 Jun 23
RZV is a non-live, recombinant sub-unit vaccine that combines antigen, glycoprotein E, with an adjuvant system, AS01B to…
27 Jun 23
The proof-of-concept trial showed that 54% of participants treated with nipocalimab met the primary endpoint of live birth…
27 Jun 23
The funding was led by AdBio partners, with co-syndication from M Ventures, Johnson & Johnson Innovation – JJDC…